Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,075.22 -29.78 (-2.70%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $942, reflecting strong market interest and confidence in the company's growth potential.
  • Eli Lilly and Co recently reported impressive quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial health.
  • The company has a strong market capitalization of $1.00 trillion, showcasing its stability and position as a leader in the pharmaceutical industry.

Cons of Eli Lilly and Company

  • Recent healthcare sector weakness may impact the overall performance of Eli Lilly and Co, despite its individual strengths.
  • The company's P/E ratio of 37.89 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • With a debt-to-equity ratio of 1.26, Eli Lilly and Co carries a moderate level of debt, which could pose risks if market conditions change.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.01 trillion
P/E Ratio
38.18
Consensus Rating
Moderate Buy
Consensus Price Target
$1,227.00 (+14.1% Upside)
Volume
1.15 million shares
Average Volume
3.19 million shares
Today's Range
$1,071.60
$1,106.17
50-Day Range
$851.65
$1,126.66
52-Week Range
$623.78
$1,149.10
Dividend Yield
0.63%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$222.22 -3.11 (-1.38%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Johnson & Johnson has a strong dividend profile, recently increasing its quarterly dividend to $1.34 per share, which reflects a commitment to returning value to shareholders.
  • The current stock price is around $230, which is near its 12-month high, indicating strong market performance and investor confidence.
  • The company reported earnings per share (EPS) of $2.70 for the latest quarter, exceeding analysts' expectations, showcasing its robust financial health.

Cons of Johnson & Johnson

  • Recent talc litigation headlines, including a significant jury verdict related to asbestos contamination, pose ongoing legal risks that could impact the company's reputation and financial stability.
  • Broader concerns regarding potential drug pricing pressures under current political policies may limit profit expectations for Johnson & Johnson's pharmaceutical segment.
  • Despite recent revenue growth, the company’s EPS has decreased compared to the same quarter last year, which may raise concerns about future earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$535.05 billion
P/E Ratio
25.70
Consensus Rating
Moderate Buy
Consensus Price Target
$253.04 (+13.9% Upside)
Volume
2.88 million shares
Average Volume
8.35 million shares
Today's Range
$220.84
$223.65
50-Day Range
$221.17
$244.48
52-Week Range
$149.04
$251.71
Dividend Yield
2.38%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$211.90 -5.82 (-2.67%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie recently reported strong quarterly earnings, with earnings per share of $2.65, exceeding analysts' expectations, indicating robust financial performance.
  • The company achieved a revenue of $15 billion for the quarter, reflecting a year-over-year growth of 12.4%, showcasing its ability to expand its market presence.
  • The current stock price is around $214.86, which may present a favorable entry point for investors looking to capitalize on potential future growth.

Cons of AbbVie

  • AbbVie has reported a negative return on equity of 576.45%, which may raise concerns about the company's efficiency in generating profits from its equity.
  • The stock has experienced volatility, with a 12-month high of $244.81 and a low of $180.25, indicating potential risks associated with price fluctuations.
  • Despite recent revenue growth, the company has a relatively low net margin of 5.79%, which could suggest challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$374.23 billion
P/E Ratio
104.34
Consensus Rating
Moderate Buy
Consensus Price Target
$253.43 (+19.6% Upside)
Volume
1.62 million shares
Average Volume
6.86 million shares
Today's Range
$211.51
$216.50
50-Day Range
$197.24
$218.66
52-Week Range
$181.73
$244.81
Dividend Yield
3.18%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$378.66 -1.65 (-0.43%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • UnitedHealth Group has received multiple upgrades from analysts, indicating strong confidence in its future performance. Recent ratings include a "buy" from Argus and an "overweight" from JPMorgan Chase & Co.
  • The current stock price is around $388, reflecting a solid market position and potential for growth as analysts have set a consensus price target of approximately $397.63.
  • UnitedHealth Group operates two primary business platforms, UnitedHealthcare and Optum, which diversify its revenue streams and reduce risk associated with market fluctuations.

Cons of UnitedHealth Group

  • Despite recent upgrades, there is still one analyst rating the stock as a "sell," which may indicate potential risks or concerns about the company's future performance.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 29.34, which could suggest that it is overvalued compared to its earnings, making it a riskier investment.
  • Recent insider selling, including a transaction by the CEO, may raise concerns about the company's future outlook and the confidence of its leadership in its stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$343.48 billion
P/E Ratio
28.57
Consensus Rating
Moderate Buy
Consensus Price Target
$399.50 (+5.5% Upside)
Volume
2.44 million shares
Average Volume
8.98 million shares
Today's Range
$375.92
$383.35
50-Day Range
$259.15
$400.69
52-Week Range
$234.60
$404.15
Dividend Yield
2.32%
Merck & Co., Inc. stock logo

5. Merck & Co., Inc. NYSE:MRK

$114.58 -4.14 (-3.49%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $120, reflecting a strong market position and investor confidence.
  • Merck has demonstrated consistent revenue growth, with recent quarterly revenue surpassing analyst expectations, indicating robust business performance.
  • The company has a solid market capitalization of approximately $297 billion, suggesting stability and a strong presence in the pharmaceutical industry.

Cons of Merck & Co., Inc.

  • The price-to-earnings (P/E) ratio is relatively high at around 34.52, which may indicate that the stock is overvalued compared to its earnings.
  • Recent downgrades from analysts suggest a cautious outlook, with some firms lowering their ratings on the stock, which could impact investor sentiment.
  • Merck's debt-to-equity ratio of 1.02 indicates a significant level of debt, which could pose risks if the company faces financial challenges.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$282.91 billion
P/E Ratio
32.27
Consensus Rating
Moderate Buy
Consensus Price Target
$128.18 (+11.9% Upside)
Volume
3.72 million shares
Average Volume
10.83 million shares
Today's Range
$114.42
$117.96
50-Day Range
$109.33
$123.25
52-Week Range
$75.40
$125.14
Dividend Yield
2.86%
Novartis stock logo

6. Novartis NYSE:NVS

$145.35 -4.82 (-3.21%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $146, which is significantly lower than its twelve-month high, indicating potential for price appreciation.
  • Novartis AG has a strong market capitalization of approximately $272.84 billion, reflecting its stability and prominence in the pharmaceutical industry.
  • The company recently declared a substantial annual dividend of $4.773 per share, showcasing its commitment to returning value to shareholders.

Cons of Novartis

  • The company reported a decline in quarterly revenue compared to the previous year, which may raise concerns about its growth trajectory.
  • Novartis AG's earnings per share (EPS) recently missed analysts' expectations, which could indicate potential challenges in meeting future financial targets.
  • With a price-to-earnings (P/E) ratio of around 19.97, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$277.56 billion
P/E Ratio
20.84
Consensus Rating
Hold
Consensus Price Target
$141.20 (-2.9% Downside)
Volume
1.21 million shares
Average Volume
1.95 million shares
Today's Range
$144.72
$147.50
50-Day Range
$142.99
$155.16
52-Week Range
$112.34
$170.46
Dividend Yield
2.05%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$44.12 -1.46 (-3.19%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $46, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • Recent reports indicate a surge in demand for Wegovy, a weight management medication, with over 2 million prescriptions filled since January, suggesting strong market potential and revenue growth.
  • Analysts have a consensus rating of "Hold" with a target price of approximately $65.56, indicating potential upside for investors if the stock approaches this target.

Cons of Novo Nordisk A/S

  • Recent downgrades from several analysts, including a shift from "buy" to "hold" ratings, may indicate a lack of confidence in the stock's short-term performance.
  • The stock has experienced volatility, with a 12-month high of $81.44 and a low of $35.12, suggesting potential risks for investors concerned about price fluctuations.
  • Market conditions and regulatory changes in the pharmaceutical industry could impact future earnings, making it a riskier investment in an uncertain environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$197.00 billion
P/E Ratio
10.36
Consensus Rating
Hold
Consensus Price Target
$65.56 (+48.6% Upside)
Volume
6.91 million shares
Average Volume
20.72 million shares
Today's Range
$43.79
$45.39
50-Day Range
$35.28
$47.13
52-Week Range
$35.12
$81.44
Dividend Yield
3.83%
Thermo Fisher Scientific stock logo

8. Thermo Fisher Scientific NYSE:TMO

$490.18 -2.33 (-0.47%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $448, which may present a buying opportunity for investors looking for value in the market.
  • Thermo Fisher Scientific Inc. has a strong market capitalization of approximately $166.61 billion, indicating a robust financial position and stability in the industry.
  • Recent analyst ratings show a consensus of "Moderate Buy," with multiple firms setting price targets above the current stock price, suggesting potential for growth.

Cons of Thermo Fisher Scientific

  • Recent insider selling, including significant transactions by the CEO and COO, may raise concerns about the company's future performance and insider confidence.
  • Analysts have recently lowered their price targets, indicating a potential shift in market sentiment and expectations for the company's growth.
  • The stock has experienced fluctuations, with a 1-year high of $643.99 and a low of $385.46, suggesting volatility that could deter conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$182.12 billion
P/E Ratio
26.94
Consensus Rating
Moderate Buy
Consensus Price Target
$616.10 (+25.7% Upside)
Volume
1.13 million shares
Average Volume
2.36 million shares
Today's Range
$483.50
$495.18
50-Day Range
$438.16
$531.69
52-Week Range
$385.46
$643.99
Dividend Yield
0.38%
Amgen stock logo

9. Amgen NASDAQ:AMGN

$327.58 -9.21 (-2.73%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $390, reflecting a positive outlook from analysts who have set target prices as high as $400.
  • Amgen Inc. reported earnings per share (EPS) of $5.15 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance.
  • The company has a solid revenue growth of 5.8% year-over-year, showcasing its ability to expand its market presence and product offerings.

Cons of Amgen

  • Despite positive earnings, the stock has received mixed ratings from analysts, with a consensus rating of "Hold," indicating uncertainty in its future performance.
  • Two analysts have issued "Sell" ratings, suggesting that there may be concerns about the company's growth potential or market conditions.
  • The dividend payout ratio is 70.15%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$176.66 billion
P/E Ratio
22.78
Consensus Rating
Hold
Consensus Price Target
$355.19 (+8.4% Upside)
Volume
737,978 shares
Average Volume
2.70 million shares
Today's Range
$326.35
$333.83
50-Day Range
$324.39
$355.60
52-Week Range
$267.83
$391.29
Dividend Yield
3.00%
Gilead Sciences stock logo

10. Gilead Sciences NASDAQ:GILD

$131.10 -3.33 (-2.48%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Recent analyst upgrades have increased price targets significantly, with some firms setting targets as high as $170, indicating strong potential for stock appreciation.
  • The current stock price is around $132, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • Gilead Sciences, Inc. has a solid reputation in antiviral therapies and is expanding into oncology and cell therapy, which are high-demand areas in healthcare.

Cons of Gilead Sciences

  • Recent insider selling by senior executives, including the CFO, may create negative sentiment around the stock, even though these transactions were pre-planned.
  • Daiwa Securities recently trimmed its price target from $161 to $150, indicating a potential moderation in analyst expectations for the stock's performance.
  • Some analysts have downgraded their ratings, with Wall Street Zen moving from a "strong-buy" to a "hold," suggesting caution among some market participants.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$162.52 billion
P/E Ratio
17.83
Consensus Rating
Moderate Buy
Consensus Price Target
$156.93 (+19.7% Upside)
Volume
2.11 million shares
Average Volume
6.73 million shares
Today's Range
$130.53
$133.99
50-Day Range
$127.75
$142.09
52-Week Range
$104.46
$157.29
Dividend Yield
2.41%
Abbott Laboratories stock logo

11. Abbott Laboratories NYSE:ABT

$87.69 +2.09 (+2.44%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $91.50, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Abbott Laboratories reported a revenue increase of 7.8% compared to the same quarter last year, indicating strong growth potential and demand for its products.
  • The company has a solid return on equity of 17.62%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of Abbott Laboratories

  • Insider selling has been observed, with executives selling shares recently, which may raise concerns about their confidence in the company's future performance.
  • The stock has experienced fluctuations, with a one-year high of $139.06 and a low of $81.97, indicating potential volatility that could deter risk-averse investors.
  • The P/E ratio of 24.49 suggests that the stock may be overvalued compared to its earnings, which could lead to a correction in price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$152.61 billion
P/E Ratio
24.54
Consensus Rating
Moderate Buy
Consensus Price Target
$119.09 (+35.8% Upside)
Volume
4.53 million shares
Average Volume
11.81 million shares
Today's Range
$85.60
$87.86
50-Day Range
$82.58
$107.16
52-Week Range
$81.97
$139.06
Dividend Yield
2.94%
Intuitive Surgical stock logo

12. Intuitive Surgical NASDAQ:ISRG

$418.18 -6.46 (-1.52%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $438, which may present a buying opportunity for investors looking for growth in the medical technology sector.
  • Intuitive Surgical, Inc. reported a significant year-over-year revenue increase of 23%, indicating strong demand for its robotic-assisted surgical systems.
  • The company has a robust net margin of over 28%, showcasing its ability to generate profit efficiently from its operations.

Cons of Intuitive Surgical

  • The stock has experienced a decline of approximately 7% since the last earnings report, raising concerns about its short-term performance.
  • Intuitive Surgical, Inc. has lagged behind the market over the past six months, which may deter valuation-sensitive investors.
  • Insider selling has been noted, with executives reducing their positions, which can sometimes signal a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$147.92 billion
P/E Ratio
50.63
Consensus Rating
Moderate Buy
Consensus Price Target
$576.71 (+37.9% Upside)
Volume
1.21 million shares
Average Volume
2.06 million shares
Today's Range
$414.14
$423.95
50-Day Range
$418.55
$483.62
52-Week Range
$414.14
$603.88
Dividend Yield
N/A
Pfizer stock logo

13. Pfizer NYSE:PFE

$25.68 -0.50 (-1.89%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $28, which is near its 52-week high, indicating strong market performance and investor confidence.
  • Pfizer Inc. recently reported quarterly earnings that exceeded analysts' expectations, showcasing a solid revenue growth of over 5% year-over-year, which reflects the company's robust financial health.
  • The company has advanced new formulations for migraine treatment and tafamidis, indicating ongoing innovation and potential for future revenue streams.

Cons of Pfizer

  • The termination of an early Phase 1 KRAS cancer trial may signal setbacks in Pfizer's oncology pipeline, which could impact future growth prospects.
  • There are ongoing concerns regarding patent risks and competitive pressures that could limit the company's market position and profitability.
  • Despite recent pipeline advancements, some analysts remain cautious, indicating that the stock may face challenges in sustaining its current valuation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.28 billion
P/E Ratio
19.59
Consensus Rating
Hold
Consensus Price Target
$28.82 (+12.2% Upside)
Volume
18.30 million shares
Average Volume
41.36 million shares
Today's Range
$25.48
$25.91
50-Day Range
$25.31
$28.56
52-Week Range
$23.06
$28.75
Dividend Yield
6.57%
Danaher stock logo

14. Danaher NYSE:DHR

$180.13 -2.54 (-1.39%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The company recently reported earnings per share (EPS) of $2.06, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • Danaher Co. has a solid dividend yield of approximately 1.0%, providing investors with a steady income stream through dividends, which are paid quarterly.
  • The current stock price is around $208, reflecting a stable valuation in the market, which may attract investors looking for reliable investments.

Cons of Danaher

  • The company’s revenue for the last quarter was $5.95 billion, slightly below analyst expectations, which may raise concerns about its ability to meet future growth targets.
  • Danaher Co. has a relatively high dividend payout ratio of 30.95%, which could limit its ability to reinvest profits back into the business for expansion.
  • Insider selling activity, such as the recent sale of 1,320 shares by an executive vice president, may signal a lack of confidence in the company's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$127.42 billion
P/E Ratio
34.82
Consensus Rating
Moderate Buy
Consensus Price Target
$238.24 (+32.3% Upside)
Volume
1.33 million shares
Average Volume
4.36 million shares
Today's Range
$178.99
$182.55
50-Day Range
$161.95
$198.58
52-Week Range
$160.93
$242.80
Dividend Yield
0.88%
Stryker stock logo

15. Stryker NYSE:SYK

$302.62 -2.47 (-0.81%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $395, which reflects a moderate buy rating from analysts, indicating potential for growth.
  • Stryker Co. has a solid dividend yield of 1.1%, providing investors with a steady income stream through its annualized dividend of $3.52.
  • The company has a strong payout ratio of 40.74%, suggesting that it is returning a healthy portion of its earnings to shareholders while still retaining enough for growth.

Cons of Stryker

  • The company recently reported earnings per share of $2.60, which missed analysts' expectations, indicating potential challenges in meeting growth targets.
  • Revenue for the last quarter was below expectations at $6.02 billion, which may raise concerns about the company's ability to drive sales growth in the near term.
  • Some analysts have lowered their price targets for Stryker Co., reflecting a cautious outlook on the stock's performance in the coming months.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$115.98 billion
P/E Ratio
35.02
Consensus Rating
Moderate Buy
Consensus Price Target
$395.48 (+30.7% Upside)
Volume
1.22 million shares
Average Volume
2.29 million shares
Today's Range
$297.88
$305.32
50-Day Range
$282.85
$347.28
52-Week Range
$281.00
$404.87
Dividend Yield
1.15%
CVS Health stock logo

16. CVS Health NYSE:CVS

$90.44 -0.54 (-0.59%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The current stock price is around $93, reflecting a strong market position and potential for growth.
  • Recent earnings reports showed CVS Health Co. exceeding analysts' expectations, indicating robust financial health and operational efficiency.
  • Multiple analysts have recently raised their price targets for CVS Health Co., suggesting confidence in the company's future performance.

Cons of CVS Health

  • Insider selling has been significant, with executives offloading large amounts of stock, which may signal concerns about the company's future performance.
  • The company's debt-to-equity ratio is relatively high, indicating a reliance on borrowed funds which could pose risks in a rising interest rate environment.
  • Despite recent growth, the net margin is low, suggesting that profitability may be under pressure from operational costs.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$115.23 billion
P/E Ratio
39.78
Consensus Rating
Moderate Buy
Consensus Price Target
$99.68 (+10.2% Upside)
Volume
1.68 million shares
Average Volume
8.52 million shares
Today's Range
$90.19
$91.85
50-Day Range
$69.98
$98.14
52-Week Range
$58.50
$98.43
Dividend Yield
2.92%
Bristol Myers Squibb stock logo

17. Bristol Myers Squibb NYSE:BMY

$54.78 -2.40 (-4.19%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company is set to unveil new data at ASCO 2026, which may highlight the strength of its oncology portfolio and next-generation pipeline, potentially boosting investor confidence in future growth.
  • Bristol-Myers Squibb has a diverse product lineup, including recent advancements in treatments for various cancers and other serious diseases, which positions it well in the biopharmaceutical market.
  • The current stock price is around $61.31, reflecting a consensus target price that suggests potential for growth based on analysts' ratings.

Cons of Bristol Myers Squibb

  • There are ongoing concerns regarding patent expirations, which could impact the company's revenue from key products and create uncertainty for investors.
  • Market commentary suggests a cautious balance between the potential of the pipeline and the risks associated with upcoming data readouts, which may affect stock performance.
  • Some analysts have issued "underweight" ratings, indicating that they believe the stock may not perform as well as the market or its peers.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$111.87 billion
P/E Ratio
15.39
Consensus Rating
Hold
Consensus Price Target
$61.31 (+11.9% Upside)
Volume
7.52 million shares
Average Volume
12.16 million shares
Today's Range
$54.71
$57.45
50-Day Range
$55.62
$61.79
52-Week Range
$42.52
$62.89
Dividend Yield
4.41%
Vertex Pharmaceuticals stock logo

18. Vertex Pharmaceuticals NASDAQ:VRTX

$437.42 -10.12 (-2.26%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $486, reflecting strong market interest and potential for growth.
  • Vertex Pharmaceuticals Incorporated has received multiple "buy" ratings from analysts, indicating confidence in its future performance.
  • The company is recognized for its innovative therapies in cystic fibrosis, which have significantly improved treatment standards, showcasing its commitment to research-driven drug development.

Cons of Vertex Pharmaceuticals

  • Insider selling activity has been noted, with executives reducing their positions, which may raise concerns about the company's short-term prospects.
  • The stock has experienced fluctuations, and recent sales by executives could indicate potential volatility ahead.
  • Despite positive ratings, the consensus price target is lower than some recent highs, suggesting that the stock may face resistance in achieving higher valuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$110.99 billion
P/E Ratio
25.94
Consensus Rating
Moderate Buy
Consensus Price Target
$555.91 (+27.1% Upside)
Volume
402,373 shares
Average Volume
1.38 million shares
Today's Range
$433.26
$443.54
50-Day Range
$423.24
$458.05
52-Week Range
$362.50
$507.92
Dividend Yield
N/A
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$43.02 -0.65 (-1.50%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi recently increased its annual dividend to $2.4225, reflecting a strong commitment to returning value to shareholders.
  • The current stock price is around $45.95, which is considered attractive given the company's solid fundamentals.
  • Analysts have a consensus rating of "Hold" with a price target of $51.00, indicating potential for price appreciation.

Cons of Sanofi

  • Despite the recent dividend increase, the payout ratio is 49.44%, which may limit future dividend growth.
  • Sanofi's quick ratio of 0.22 indicates potential liquidity issues, as it suggests the company may struggle to meet short-term obligations.
  • Recent analyst ratings show a mix of "Hold" and "Buy," with some analysts downgrading their ratings, which may indicate uncertainty in the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$104.30 billion
P/E Ratio
12.02
Consensus Rating
Hold
Consensus Price Target
$51.00 (+18.6% Upside)
Volume
1.57 million shares
Average Volume
3.58 million shares
Today's Range
$42.97
$43.60
50-Day Range
$42.42
$48.18
52-Week Range
$42.33
$52.68
Dividend Yield
4.04%
GSK stock logo

20. GSK NYSE:GSK

$49.34 -1.20 (-2.36%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $51.65, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc has a solid dividend payout ratio of approximately 38.8%, indicating that the company is generating sufficient earnings to cover its dividend payments, which can provide a steady income stream for investors.
  • The company reported a significant increase in revenue, with a year-over-year growth of 6.2%, showcasing its ability to expand and perform well in the market.

Cons of GSK

  • GSK plc has decreased its dividend payment by an average of 0.1% annually over the last three years, which may concern income-focused investors looking for consistent returns.
  • The company has a relatively high debt-to-equity ratio of 0.92, suggesting that it relies on debt financing, which can be risky in volatile market conditions.
  • Despite recent revenue growth, the company faces intense competition in the pharmaceutical industry, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$100.19 billion
P/E Ratio
12.83
Consensus Rating
Reduce
Consensus Price Target
$53.00 (+7.4% Upside)
Volume
1.85 million shares
Average Volume
4.86 million shares
Today's Range
$49.18
$50.14
50-Day Range
$49.66
$59.19
52-Week Range
$35.45
$61.69
Dividend Yield
3.59%
Medtronic stock logo

21. Medtronic NYSE:MDT

$74.38 +0.57 (+0.77%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $78, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Medtronic plc has demonstrated strong financial performance, with a recent quarterly revenue increase of 5.8% year-over-year, indicating robust demand for its products.
  • The company has a solid dividend yield of approximately 3.6%, providing a steady income stream for investors, which is particularly attractive in a low-interest-rate environment.

Cons of Medtronic

  • Recent market commentary has highlighted concerns regarding acquisition costs and execution risks associated with Medtronic's recent $650 million deal, which may impact investor confidence.
  • The company's price-to-earnings ratio is around 21.54, which could be considered high compared to industry averages, suggesting that the stock may be overvalued.
  • Medtronic plc's dividend payout ratio is approximately 79.11%, indicating that a significant portion of earnings is being paid out as dividends, which may limit reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$95.46 billion
P/E Ratio
20.71
Consensus Rating
Moderate Buy
Consensus Price Target
$106.45 (+43.1% Upside)
Volume
7.10 million shares
Average Volume
8.91 million shares
Today's Range
$73.77
$75.03
50-Day Range
$73.73
$88.65
52-Week Range
$73.67
$106.33
Dividend Yield
3.85%
McKesson stock logo

22. McKesson NYSE:MCK

$734.37 -8.07 (-1.09%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $775, which reflects a strong performance in the healthcare sector.
  • McKesson Co. has received multiple "buy" ratings from analysts, indicating positive market sentiment and potential for growth.
  • The company reported a quarterly revenue increase of 6.0% compared to the same quarter last year, showcasing its ability to grow even in challenging market conditions.

Cons of McKesson

  • The company has a negative return on equity of 345.35%, which may indicate inefficiencies in generating profit from shareholders' equity.
  • McKesson Co. reported earnings that fell short of revenue expectations, which could raise concerns about its ability to meet future financial targets.
  • Insider selling activity has been noted, with significant shares sold by executives, which may signal a lack of confidence in the company's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.27 billion
P/E Ratio
19.09
Consensus Rating
Moderate Buy
Consensus Price Target
$968.87 (+31.9% Upside)
Volume
296,268 shares
Average Volume
899,599 shares
Today's Range
$732.44
$743.00
50-Day Range
$724.87
$898.82
52-Week Range
$637.00
$999.00
Dividend Yield
0.44%
Elevance Health stock logo

23. Elevance Health NYSE:ELV

$400.82 +7.63 (+1.94%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$86.91 billion
P/E Ratio
17.02
Consensus Rating
Moderate Buy
Consensus Price Target
$407.05 (+1.6% Upside)
Volume
364,489 shares
Average Volume
1.82 million shares
Today's Range
$390.82
$400.81
50-Day Range
$284.64
$402.32
52-Week Range
$273.71
$408.00
Dividend Yield
1.75%
HCA Healthcare stock logo

24. HCA Healthcare NYSE:HCA

$372.69 -5.85 (-1.55%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $540, reflecting a strong market position and potential for growth.
  • HCA Healthcare, Inc. reported a revenue increase of 4.3% compared to the same quarter last year, indicating robust operational performance.
  • Analysts have a consensus rating of "Moderate Buy" for HCA Healthcare, Inc., suggesting positive sentiment among investment professionals.

Cons of HCA Healthcare

  • The company missed the consensus earnings estimate by $0.04, which may raise concerns about its ability to meet financial expectations.
  • HCA Healthcare, Inc. has a negative return on equity of 295.93%, indicating potential inefficiencies in generating profit from shareholders' equity.
  • Recent downgrades from several investment firms, including a reduction in target prices, may signal a lack of confidence in the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$82.72 billion
P/E Ratio
12.82
Consensus Rating
Moderate Buy
Consensus Price Target
$515.77 (+38.4% Upside)
Volume
1.09 million shares
Average Volume
1.18 million shares
Today's Range
$367.43
$375.57
50-Day Range
$377.72
$507.17
52-Week Range
$330.00
$556.52
Dividend Yield
0.82%
Cigna Group stock logo

25. Cigna Group NYSE:CI

$273.61 -3.79 (-1.37%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group has shown a solid quarterly revenue increase of approximately 4.6% compared to the same quarter last year, indicating strong business performance and growth potential.
  • The current stock price is around $288.91, which reflects a stable valuation in the market, making it an attractive option for investors looking for growth in the health services sector.
  • The company has a favorable dividend yield of 2.1%, providing investors with a steady income stream through its quarterly dividend payments, which are indicative of financial health and shareholder return strategies.

Cons of Cigna Group

  • Insider selling has been notable, with corporate insiders selling over 205,000 shares recently, which may raise concerns about their confidence in the company's future performance.
  • The payout ratio is currently at 26.45%, which, while manageable, could limit the company's ability to reinvest in growth opportunities if earnings do not continue to rise.
  • Recent target price adjustments by analysts, while still positive, indicate some caution, with slight reductions in price targets suggesting potential volatility in the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$72.34 billion
P/E Ratio
11.59
Consensus Rating
Moderate Buy
Consensus Price Target
$339.50 (+24.1% Upside)
Volume
331,232 shares
Average Volume
1.69 million shares
Today's Range
$273.07
$277.98
50-Day Range
$257.97
$300.36
52-Week Range
$239.51
$338.89
Dividend Yield
2.25%
Boston Scientific stock logo

26. Boston Scientific NYSE:BSX

$47.46 -0.85 (-1.76%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $48.32, which may present a buying opportunity for investors looking for value in the medical device sector.
  • Boston Scientific Co. has shown strong financial performance, reporting a quarterly revenue increase of 11.6% year-over-year, indicating robust demand for its products.
  • The company has a solid return on equity of 19.17%, suggesting effective management and profitability, which can be attractive to investors seeking growth.

Cons of Boston Scientific

  • Analysts have recently downgraded target prices for the stock, with some reducing their estimates significantly, which may reflect concerns about future growth potential.
  • The company has a relatively high price-to-earnings ratio of 20.22, which could indicate that the stock is overvalued compared to its earnings, making it a riskier investment.
  • Boston Scientific Co. has a beta of 0.62, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$70.49 billion
P/E Ratio
19.84
Consensus Rating
Moderate Buy
Consensus Price Target
$87.42 (+84.2% Upside)
Volume
11.98 million shares
Average Volume
17.33 million shares
Today's Range
$47.37
$48.66
50-Day Range
$48.32
$70.08
52-Week Range
$47.37
$109.50
Dividend Yield
N/A
Regeneron Pharmaceuticals stock logo

27. Regeneron Pharmaceuticals NASDAQ:REGN

$603.21 -11.57 (-1.88%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $705, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Regeneron Pharmaceuticals, Inc. has a low dividend payout ratio of approximately 9.16%, indicating that the company retains a significant portion of its earnings for reinvestment, which could lead to future growth.
  • Recent analyst ratings show a consensus of "Moderate Buy," with two analysts giving a Strong Buy rating, suggesting confidence in the company's future performance.

Cons of Regeneron Pharmaceuticals

  • Recent insider selling, including significant transactions by directors, may raise concerns about the company's short-term outlook and could indicate a lack of confidence among insiders.
  • Some analysts have downgraded their ratings, with Zacks Research cutting the stock from a "strong-buy" to a "hold," which may suggest caution among market experts.
  • The stock has experienced fluctuations, with recent price targets being lowered by various brokerages, indicating potential volatility in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$63.74 billion
P/E Ratio
14.69
Consensus Rating
Moderate Buy
Consensus Price Target
$792.65 (+31.4% Upside)
Volume
414,375 shares
Average Volume
819,550 shares
Today's Range
$602.00
$614.00
50-Day Range
$614.78
$777.25
52-Week Range
$476.49
$821.11
Dividend Yield
0.61%
argenex stock logo

28. argenex NASDAQ:ARGX

$837.80 +1.81 (+0.22%)
As of 01:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $783, indicating a strong market presence and potential for growth.
  • Guggenheim recently raised its target price for argenx SE to $1,135, suggesting a potential upside of nearly 45% from current levels.
  • Argentx SE has a robust pipeline, including its lead product candidate, efgartigimod, which targets multiple autoimmune diseases, enhancing its market potential.

Cons of argenex

  • Despite positive analyst ratings, the stock has experienced fluctuations, with a recent decline of about 0.5% in value.
  • Some analysts have downgraded their ratings, indicating mixed sentiments about the stock's short-term performance.
  • The company operates in a highly competitive biotechnology sector, which can pose risks to its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.08 billion
P/E Ratio
37.29
Consensus Rating
Moderate Buy
Consensus Price Target
$1,019.50 (+21.7% Upside)
Volume
124,536 shares
Average Volume
349,923 shares
Today's Range
$825.55
$838.47
50-Day Range
$663.93
$849.04
52-Week Range
$510.05
$934.62
Dividend Yield
N/A
Cencora stock logo

29. Cencora NYSE:COR

$265.43 -3.93 (-1.46%)
As of 01:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The stock has a consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards its future performance.
  • Recent price targets from analysts suggest a potential upside, with estimates ranging from $331.00 to $360.00, indicating room for growth.
  • The current stock price is around $254.90, which may present a buying opportunity for investors looking for value.

Cons of Cencora

  • Recent target price reductions by analysts, including a cut from Citigroup to $355.00, may indicate concerns about the company's short-term performance.
  • The stock has experienced volatility, with a one-year low of $244.82, suggesting potential risks for investors.
  • Cencora, Inc. has a relatively high debt-to-equity ratio of 3.62, which may raise concerns about its financial leverage and risk profile.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.62 billion
P/E Ratio
20.35
Consensus Rating
Moderate Buy
Consensus Price Target
$380.25 (+43.3% Upside)
Volume
594,348 shares
Average Volume
1.54 million shares
Today's Range
$262.67
$269.36
50-Day Range
$253.20
$332.06
52-Week Range
$244.82
$377.54
Dividend Yield
0.89%
Edwards Lifesciences stock logo

30. Edwards Lifesciences NYSE:EW

$87.95 +1.48 (+1.71%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $81, which is within a reasonable range compared to its 12-month high of $87.89, indicating potential for growth.
  • The company has demonstrated strong financial performance, with a recent quarterly revenue increase of 16.7% year-over-year, showcasing its ability to grow in a competitive market.
  • Edwards Lifesciences Co. has a solid quick ratio of 3.63, indicating strong short-term liquidity and the ability to cover its current liabilities without relying on inventory.

Cons of Edwards Lifesciences

  • The price-to-earnings (P/E) ratio is relatively high at 45.71, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling activity has been noted, with significant shares sold recently, which could signal a lack of confidence in the company's future performance from those closest to it.
  • The company has set its FY 2026 earnings per share guidance at 2.950-3.050, which may not meet investor expectations if growth slows or market conditions change.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.63 billion
P/E Ratio
46.77
Consensus Rating
Moderate Buy
Consensus Price Target
$95.65 (+8.8% Upside)
Volume
2.92 million shares
Average Volume
4.82 million shares
Today's Range
$86.25
$88.72
50-Day Range
$77.11
$87.58
52-Week Range
$72.30
$88.72
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

31. Takeda Pharmaceutical NYSE:TAK

$15.16 -0.80 (-4.98%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Takeda Pharmaceutical Company Limited is expected to launch several new products, including TAK-881, which has the potential to significantly improve treatment for primary immunodeficiency disease by delivering required doses in a smaller volume.
  • The company is undergoing a transformation program aimed at enhancing operational efficiency, with projected annualized gross savings exceeding JPY 200 billion by fiscal 2028, which could positively impact profitability.
  • The current stock price is around $16.74, reflecting a stable position within the market, with a twelve-month high of $18.90, indicating potential for growth.

Cons of Takeda Pharmaceutical

  • The company is facing significant restructuring costs of JPY 170 billion this year, which could impact short-term financial performance and investor sentiment.
  • Takeda has not provided growth projections beyond fiscal 2026, which may create uncertainty for investors regarding long-term profitability and market positioning.
  • The company’s debt-to-equity ratio stands at 0.56, indicating a moderate level of debt that could pose risks if not managed effectively, especially in a fluctuating market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.26 billion
P/E Ratio
38.89
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
2.27 million shares
Average Volume
3.02 million shares
Today's Range
$15.08
$15.50
50-Day Range
$15.87
$18.77
52-Week Range
$12.99
$18.90
Dividend Yield
3.15%
Cardinal Health stock logo

32. Cardinal Health NYSE:CAH

$194.45 -2.35 (-1.19%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The company recently reported earnings that exceeded expectations, with an EPS of $3.17, indicating strong profitability and effective management.
  • Cardinal Health, Inc. has shown a significant revenue increase of 11.0% compared to the same quarter last year, reflecting robust growth in its operations.
  • The current stock price is around $241.80, which analysts consider to be a reasonable entry point given the company's growth potential and recent performance.

Cons of Cardinal Health

  • Despite the positive EPS results, the company missed revenue expectations, which can lead to short-term selling pressure and volatility in the stock price.
  • Cardinal Health, Inc. reported a negative return on equity of 92.61%, indicating that the company is not generating sufficient profit relative to shareholder equity, which may concern potential investors.
  • Recent GAAP results showed a decline in operating earnings and EPS due to a significant goodwill impairment charge, which can affect investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.52 billion
P/E Ratio
29.71
Consensus Rating
Moderate Buy
Consensus Price Target
$241.80 (+24.3% Upside)
Volume
744,536 shares
Average Volume
1.89 million shares
Today's Range
$194.00
$196.85
50-Day Range
$182.62
$216.06
52-Week Range
$137.75
$233.60
Dividend Yield
1.04%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$563.76 +0.23 (+0.04%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $640, which reflects a significant adjustment from previous highs, potentially offering a buying opportunity for investors looking for value.
  • IDEXX Laboratories, Inc. reported a strong earnings performance recently, with earnings per share (EPS) of $3.47, surpassing analysts' expectations, indicating robust financial health.
  • The company has shown impressive revenue growth, with a 14.3% increase compared to the same quarter last year, suggesting strong demand for its diagnostic products and services.

Cons of IDEXX Laboratories

  • The stock has experienced price target reductions from multiple analysts, indicating a potential lack of confidence in short-term growth prospects.
  • IDEXX Laboratories, Inc. has a relatively high price-to-earnings (P/E) ratio of 40.19, which may suggest that the stock is overvalued compared to its earnings, posing a risk for new investors.
  • The company has a beta of 1.58, indicating higher volatility compared to the market, which could lead to greater price fluctuations and risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.58 billion
P/E Ratio
41.62
Consensus Rating
Moderate Buy
Consensus Price Target
$751.00 (+33.2% Upside)
Volume
220,018 shares
Average Volume
547,187 shares
Today's Range
$552.25
$570.56
50-Day Range
$528.68
$591.84
52-Week Range
$504.56
$769.98
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

34. Becton, Dickinson and Company NYSE:BDX

$147.14 +0.02 (+0.01%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $154, which may present a buying opportunity given analysts' recent price target increases.
  • Becton, Dickinson and Company has raised its full-year adjusted EPS guidance, indicating strong financial performance and growth potential.
  • The company returned approximately $2.3 billion to shareholders recently, including significant share repurchases, which can enhance shareholder value.

Cons of Becton, Dickinson and Company

  • The company is currently facing an FDA warning letter related to its El Paso facility, which could impact its reputation and operational capabilities.
  • Despite recent price target increases, some analysts have downgraded their ratings, indicating mixed sentiment in the market.
  • There are concerns regarding the company's debt levels, as it ended the quarter with net leverage above its long-term target, which could limit financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.53 billion
P/E Ratio
37.23
Consensus Rating
Hold
Consensus Price Target
$183.64 (+24.8% Upside)
Volume
809,977 shares
Average Volume
2.88 million shares
Today's Range
$145.13
$147.92
50-Day Range
$142.36
$158.63
52-Week Range
$127.59
$187.35
Dividend Yield
2.85%
Alnylam Pharmaceuticals stock logo

35. Alnylam Pharmaceuticals NASDAQ:ALNY

$299.20 -2.79 (-0.92%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The current stock price is around $294, which may present a buying opportunity for investors looking for potential growth in the biopharmaceutical sector.
  • Alnylam Pharmaceuticals, Inc. has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance.
  • Recent upgrades in analyst ratings, including a shift from "hold" to "buy," suggest positive sentiment and potential for stock appreciation.

Cons of Alnylam Pharmaceuticals

  • Insider selling has occurred recently, with executives selling over 21,000 shares, which may raise concerns about the company's future performance.
  • The stock has experienced volatility, with a 52-week high of $495 and a low of $284, indicating potential risks associated with price fluctuations.
  • Analysts have adjusted target prices downward, which could signal caution regarding the company's near-term growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.99 billion
P/E Ratio
81.84
Consensus Rating
Moderate Buy
Consensus Price Target
$463.13 (+54.8% Upside)
Volume
442,983 shares
Average Volume
1.25 million shares
Today's Range
$296.72
$303.98
50-Day Range
$284.84
$339.41
52-Week Range
$284.28
$495.55
Dividend Yield
N/A
Teva Pharmaceutical Industries stock logo

36. Teva Pharmaceutical Industries NYSE:TEVA

$34.22 -1.10 (-3.11%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$39.36 billion
P/E Ratio
25.74
Consensus Rating
Moderate Buy
Consensus Price Target
$41.78 (+22.1% Upside)
Volume
2.48 million shares
Average Volume
7.86 million shares
Today's Range
$33.84
$34.77
50-Day Range
$28.37
$36.36
52-Week Range
$14.99
$37.35
Dividend Yield
N/A
Haleon stock logo

37. Haleon NYSE:HLN

$8.88 -0.19 (-2.04%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $11.06, which may present a buying opportunity for investors looking for value in the consumer healthcare sector.
  • Haleon plc has a diverse product portfolio, including well-known brands in oral health, vitamins, and over-the-counter medications, which can help stabilize revenue streams.
  • The company has a long history, founded in 1715, which may instill confidence in its operational stability and experience in the market.

Cons of Haleon

  • The company has reported a month-to-month change in shares shorted, indicating some volatility in investor confidence, which could lead to price fluctuations.
  • Institutional ownership is currently at 0%, which may suggest a lack of confidence from larger investors, potentially impacting stock stability.
  • Outstanding shares are reported as 0, which could indicate issues with share availability or trading, potentially complicating investment strategies.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.32 billion
P/E Ratio
22.76
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
4.54 million shares
Average Volume
8.42 million shares
Today's Range
$8.86
$8.97
50-Day Range
$8.91
$10.24
52-Week Range
$8.71
$11.42
Dividend Yield
2.79%
Humana stock logo

38. Humana NYSE:HUM

$324.38 +18.96 (+6.21%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Humana Inc. has recently seen an upgrade in its stock rating from "strong sell" to "hold," indicating improved sentiment among analysts.
  • Analysts have raised the target price for Humana Inc. to around $255, suggesting potential upside for investors despite recent market volatility.
  • The current stock price is approximately $304.95, reflecting a strong market position and investor interest.

Cons of Humana

  • Recent earnings estimates for FY2026 and FY2027 have been cut, signaling potential challenges in profitability moving forward.
  • Concerns have been raised about a projected large loss in Q4 2026, which could negatively impact investor confidence.
  • Despite a positive rating upgrade, the overall consensus remains a "hold," suggesting caution among analysts regarding future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.77 billion
P/E Ratio
34.54
Consensus Rating
Hold
Consensus Price Target
$272.65 (-15.9% Downside)
Volume
901,942 shares
Average Volume
1.93 million shares
Today's Range
$316.00
$333.31
50-Day Range
$166.36
$309.85
52-Week Range
$163.11
$333.31
Dividend Yield
1.16%
Agilent Technologies stock logo

39. Agilent Technologies NYSE:A

$134.62 -0.92 (-0.68%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $114.84, which may present a buying opportunity for investors looking for growth in the scientific instrumentation sector.
  • Agilent Technologies, Inc. reported a revenue increase of 7.0% compared to the same quarter last year, indicating strong business performance and potential for future growth.
  • The company has a solid return on equity of 24.49%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of Agilent Technologies

  • The company recently missed earnings expectations by a small margin, reporting $1.36 EPS compared to the consensus estimate of $1.37, which may raise concerns about its short-term performance.
  • Agilent Technologies, Inc. has seen its stock price decline from a 12-month high of $160.27, which could indicate a downward trend that investors should be cautious about.
  • With a P/E ratio of 25.35, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.03 billion
P/E Ratio
27.03
Consensus Rating
Buy
Consensus Price Target
$162.79 (+20.9% Upside)
Volume
790,503 shares
Average Volume
2.25 million shares
Today's Range
$132.88
$135.57
50-Day Range
$110.35
$135.79
52-Week Range
$108.35
$160.27
Dividend Yield
0.75%
Waters stock logo

40. Waters NYSE:WAT

$373.48 -10.09 (-2.63%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$36.70 billion
P/E Ratio
47.50
Consensus Rating
Moderate Buy
Consensus Price Target
$396.00 (+6.0% Upside)
Volume
480,868 shares
Average Volume
1.08 million shares
Today's Range
$371.04
$383.70
50-Day Range
$289.38
$384.12
52-Week Range
$275.05
$414.15
Dividend Yield
N/A
Revolution Medicines stock logo

41. Revolution Medicines NASDAQ:RVMD

$162.08 +4.60 (+2.92%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$34.42 billion
P/E Ratio
N/A
Consensus Rating
Buy
Consensus Price Target
$116.00 (-28.4% Downside)
Volume
3.47 million shares
Average Volume
3.36 million shares
Today's Range
$154.13
$164.30
50-Day Range
$92.51
$157.48
52-Week Range
$34.00
$164.30
Dividend Yield
N/A
Zoetis stock logo

42. Zoetis NYSE:ZTS

$77.92 +0.23 (+0.29%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • Norges Bank recently acquired a significant stake in Zoetis Inc., purchasing over 5.8 million shares valued at approximately $734 million, indicating strong institutional confidence in the company's future.
  • Zoetis Inc. presented at the Stifel Jaws & Paws Conference, which has helped maintain investor interest in its long-term growth potential in the animal health sector.
  • The current stock price is around $125, reflecting a stable position in the market, which may attract investors looking for reliable growth.

Cons of Zoetis

  • Brokerage coverage currently shows a consensus “Hold” rating on Zoetis Inc., suggesting analysts see limited near-term upside or downside from current levels, which may indicate a lack of strong growth catalysts.
  • Despite recent institutional investments, the overall market sentiment may be cautious, as indicated by the neutral rating from analysts, which could affect stock performance.
  • While the stock price is stable, it may not present significant growth opportunities in the near term, making it less attractive for investors seeking high returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.70 billion
P/E Ratio
12.94
Consensus Rating
Hold
Consensus Price Target
$133.92 (+71.9% Upside)
Volume
2.26 million shares
Average Volume
5.25 million shares
Today's Range
$76.59
$78.48
50-Day Range
$74.11
$122.69
52-Week Range
$72.38
$172.23
Dividend Yield
2.73%
Alcon stock logo

43. Alcon NYSE:ALC

$66.06 -0.23 (-0.35%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $87.48, which reflects a stable valuation in the market.
  • Alcon Inc. has shown a month-to-month increase in shares shorted, indicating growing investor interest and potential for upward price movement.
  • The company maintains a significant institutional ownership percentage, suggesting confidence from large investors in its long-term prospects.

Cons of Alcon

  • The fifty-two week performance shows a decline of about 7.53%, which may raise concerns about the company's recent financial health and market position.
  • Despite a recent increase in shares shorted, the overall short interest remains relatively low, which could indicate a lack of strong bullish sentiment among investors.
  • The days to cover is around 4.2, suggesting that it may take some time for short sellers to cover their positions, which could lead to volatility in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.63 billion
P/E Ratio
39.74
Consensus Rating
Moderate Buy
Consensus Price Target
$85.12 (+28.9% Upside)
Volume
823,986 shares
Average Volume
1.82 million shares
Today's Range
$64.96
$65.92
50-Day Range
$61.98
$81.35
52-Week Range
$61.83
$92.55
Dividend Yield
N/A
Natera stock logo

44. Natera NASDAQ:NTRA

$222.02 -1.35 (-0.61%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$31.79 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$256.60 (+15.6% Upside)
Volume
351,111 shares
Average Volume
1.33 million shares
Today's Range
$216.60
$224.00
50-Day Range
$182.65
$223.37
52-Week Range
$131.81
$256.36
Dividend Yield
N/A
Royalty Pharma stock logo

45. Royalty Pharma NASDAQ:RPRX

$54.22 -1.54 (-2.75%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $52.85, reflecting a strong market position and investor confidence in the company's future performance.
  • Royalty Pharma plc has received multiple upgrades from investment analysts, indicating positive sentiment and potential for growth in stock value.
  • Institutional investors own over half of the company's stock, suggesting strong backing and confidence from major financial entities.

Cons of Royalty Pharma

  • Insider sales totaling over $7.5 million in the last 90 days may raise concerns about the company's short-term outlook and could signal potential issues.
  • The company's high P/E ratio of 35.95 suggests that the stock may be overvalued compared to its earnings, which could lead to price corrections.
  • Despite recent upgrades, the stock's performance can be volatile, as indicated by its beta of 0.40, which may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.27 billion
P/E Ratio
36.94
Consensus Rating
Buy
Consensus Price Target
$53.71 (-0.9% Downside)
Volume
1.40 million shares
Average Volume
3.65 million shares
Today's Range
$53.81
$55.50
50-Day Range
$45.36
$55.76
52-Week Range
$32.65
$56.07
Dividend Yield
1.69%
IQVIA stock logo

46. IQVIA NYSE:IQV

$187.28 +5.08 (+2.79%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $178, which may present a buying opportunity for investors looking for value in the market.
  • IQVIA Holdings Inc. has demonstrated strong financial performance, reporting a revenue increase of over 8% compared to the same quarter last year, indicating robust growth potential.
  • The company has a solid return on equity of 30.50%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of IQVIA

  • The stock has experienced volatility, with a 12-month high of $247.04 and a low of $134.65, which may indicate uncertainty in its price stability.
  • Despite recent revenue growth, the company operates with a high debt-to-equity ratio of 2.20, which could pose risks if market conditions change or if interest rates rise.
  • Analysts have varied opinions on the stock, with some price targets significantly lower than the current price, suggesting potential downward pressure on the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.17 billion
P/E Ratio
23.14
Consensus Rating
Buy
Consensus Price Target
$225.69 (+20.5% Upside)
Volume
515,699 shares
Average Volume
1.91 million shares
Today's Range
$182.00
$188.57
50-Day Range
$156.42
$182.03
52-Week Range
$136.41
$247.04
Dividend Yield
N/A
Veeva Systems stock logo

47. Veeva Systems NYSE:VEEV

$187.82 +13.48 (+7.73%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The company recently reported strong quarterly earnings, exceeding analysts' expectations with a significant increase in revenue, indicating robust business performance.
  • Veeva Systems Inc. has initiated a substantial stock buyback program, which often signals that management believes the stock is undervalued, potentially leading to an increase in share price.
  • The current stock price is around $155, which may present a buying opportunity for investors looking for growth in the cloud software sector.

Cons of Veeva Systems

  • Recent price target reductions by major analysts suggest a potential decline in investor sentiment, which could lead to downward pressure on the stock price.
  • Despite strong earnings, the company faces increasing competition in the cloud software market, which could impact its market share and growth prospects.
  • Insider selling activity has been noted, which may raise concerns about the confidence of company executives in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.83 billion
P/E Ratio
34.89
Consensus Rating
Moderate Buy
Consensus Price Target
$276.52 (+47.2% Upside)
Volume
2.71 million shares
Average Volume
2.64 million shares
Today's Range
$179.32
$191.97
50-Day Range
$151.43
$186.01
52-Week Range
$148.05
$310.50
Dividend Yield
N/A
BeOne Medicines stock logo

48. BeOne Medicines NASDAQ:ONC

$276.44 -11.48 (-3.99%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$30.40 billion
P/E Ratio
61.99
Consensus Rating
Moderate Buy
Consensus Price Target
$389.15 (+40.8% Upside)
Volume
91,524 shares
Average Volume
250,659 shares
Today's Range
$276.11
$287.55
50-Day Range
$274.73
$323.87
52-Week Range
$239.25
$385.22
Dividend Yield
N/A
Centene stock logo

49. Centene NYSE:CNC

$61.70 +2.10 (+3.52%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • Recent analyst upgrades have increased the price target for Centene Co. to $68.00, suggesting a potential upside of nearly 25% from the current stock price, which is around $54.44.
  • Centene Co. has a strong market capitalization of approximately $26.88 billion, indicating a solid position in the healthcare sector, which can attract more investors.
  • The company has received multiple positive ratings from analysts, with six giving a Buy rating, reflecting confidence in its growth potential.

Cons of Centene

  • Some analysts have expressed concerns about execution, indicating that further upside will require better operational performance, which may pose risks to investors.
  • There is a lower consensus price target of around $42 from some brokerages, which is significantly below the current stock price, potentially limiting upside for investors.
  • Despite recent upgrades, several analysts maintain a cautious stance with Hold or Neutral ratings, suggesting a lack of strong conviction in the stock's immediate growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.34 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$58.94 (-4.5% Downside)
Volume
1.98 million shares
Average Volume
6.41 million shares
Today's Range
$59.47
$61.75
50-Day Range
$31.72
$59.72
52-Week Range
$25.08
$61.75
Dividend Yield
N/A
DexCom stock logo

50. DexCom NASDAQ:DXCM

$75.62 +1.88 (+2.55%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $85, reflecting a strong interest from analysts who have rated the stock with a consensus of "Moderate Buy."
  • DexCom, Inc. has shown impressive revenue growth, with quarterly revenue increasing by 15% compared to the same quarter last year, indicating strong demand for its products.
  • Institutional investors own a significant majority (97.75%) of DexCom, Inc.'s stock, suggesting confidence in the company's long-term prospects.

Cons of DexCom

  • Some analysts have issued lower target prices, with Barclays setting a target of $64, indicating potential concerns about future performance.
  • Despite revenue growth, the company faces intense competition in the medical device sector, which could impact market share and profitability.
  • There is a risk of regulatory challenges that could affect the approval and distribution of new products, potentially hindering growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.15 billion
P/E Ratio
32.28
Consensus Rating
Moderate Buy
Consensus Price Target
$82.42 (+9.0% Upside)
Volume
2.43 million shares
Average Volume
5.34 million shares
Today's Range
$72.50
$75.43
50-Day Range
$57.56
$73.74
52-Week Range
$54.11
$89.98
Dividend Yield
N/A